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Stimulation of platelets results in the liberation of arachidonic acid (AA) which is further metabolized via the cyclooxygenase or lipoxygenase (LPG) 
pathway. We have examined the effect of inhibition of LPG on (i) the ADP-induced increase of cytoplasmic Ca*+ concentration and (ii) platelet 
aggregation. Lipoxygenase inhibitors, nordi~dro~aiaretic acid {NDGA) and BW-75X, both suppressed ADP-induced Caz+-signals and aggrega- 
tion in a dose-dependent manner, with an IC,, value of l-2 pM for NDGA. Qualitatively the same effect was obtained with 4-bromophenylacyl 
bromide, the inhibitor of phospholipases 4 and C. By contrast, cyclooxygenase inhibitor indomethacin had only a negligible ffect on Caz+- signals 
and suppressed only the second phase of ADP-induced aggregation. It is concluded that the LPG pathway of AA metabolism in platelets might 
play a crucial role in ADP-induct Cazf -signal generation and platelet aggregation. 
Ca*+-signal; Platelet aggregation; Lipoxygenase inhibitor 
1. INTRODUCTION 
In platelets as well as in other cells, AA is metaboliz- 
ed through both the cyclooxygenase and lipoxygenase 
pathway (for review see [l]). The involvement of 
cyclooxygenase AA metabolites in the regulation of 
platelet functions is well established 12-41. Thus it has 
been shown that the cyclooxygenase blockade by in- 
domethacin suppresses the second phase of platelet ag- 
gregation and dense granule secretion caused by ADP 
and other ‘weak agonists’ [5,6]. Indomethacin, 
however, does not diminish the stimulus-induced in- 
crease in cytoplasmic Ca2+ concentration (Ca2+ signal) 
171. Therefore, the conclusion was drawn that throm- 
boxane A2 (TXAz), a potent aggregatory agent, syn- 
thesized from AA via the cyclooxygenase pathway [l] 
is not a prerequisite for ADP-induced Ca2+-signal 
generation [7]. 
The data concerning the role of the lipooxygenase 
pathway during AA metabolism in the mechanism of 
platelet activation are at present scant and controver- 
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sial. Thus, it has been found that the application of the 
LPG inhibitor, NDGA, caused partial inhibition of 
ADP-induced platelet aggregation [8]. However, 
IZHETE, one of the LPG metabolites of AA, upon ex- 
ternal application exerted an inhibitory influence on 
AA-induced platelet aggregation [9]. 
To date, the information concerning the role of the 
LPG pathway in mechanisms of platelet activation has 
mainly been obtained from aggregation studies. Only 
one study has demonstrated the partial inhibitory effect 
of NDGA on the Ca2+ signal induced in human 
platelets by thrombin. We failed to find any indication 
to the effect of LPG inhibitors on ADP-induced Ca2+ 
signals in platelets. On other cell types, e.g., rat 
thymocytes, Gukovskaya et al. 1121 observed that the 
blockade of LPG with NDGA suppresses the con- 
canavalin A-induced Ca2+ signal. 
The object of the present study was to examine the 
contribution of the LPG pathway during AA 
metabolism to the mechanism of Ca2+-signal genera- 
tion and platelet aggregation induced by ADP. As tools 
to study this problem, we have used two LPG in- 
hibitors, NDGA and BW-755C [ll,IZ], as well as 
4-bromophenylacyl bromide, an irreversible inhibitor 
of phospholipases AZ and C [ 11,131. The effects 
observed were compared with the action of the cycloox- 
ygenase inhibitor indomethacin [1 11. 
The results of the present study show that in human 
platelets a blockade of the LPG pathway during AA 
metabolism can cause an effective concentration- 
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dependent inhibition of both Ca2+-signal generation 
and platelet aggregation caused by ADP. 
2. EXPERIMENTAL 
Freshly drawn blood taken with ACD anticoagulant (6: 1) was cen- 
trifuged at 200 x g for 15 min to obtain platelet-rich plasma (PRP). 
The PRP was then incubated for 20 min with 20 yM Quin-2 acetox- 
ymethyl ether (Sigma) at 37°C. PRP was centrifuged after the addi- 
tion of 50 pi/ml ACD ~ticoagul~t at 350 x g for 10 min. The pellet 
was resuspended in modified Tyrode’s buffer (140 mM NaCl, 5 mM 
KCl, 1 mM MgCl2, 5 mM glucose, 10 mM Hepes, pH 6.8) to a final 
concentration of 3-4 x lOa cell/ml. Apyrase (20,ug/ml) was added 
to prevent activation by residual traces of ADP. Prior to Ca2+-signal 
measurements 100,~~l of Quin-loaded platefets were diluted to 1 ml 
with buffer (composition described above), pH 7.4, and 1 mM of 
CaCl2 was added. The Quin-2 fluorescence was measured in a Hitachi 
4000 spectrofluorimeter, the experimental details for the calibration 
of Quin-2 signals being identical to those described in the literature 
V41. 
Platelet aggregation was measured in a Chronolog (USA) lumiag- 
gregometer at 37°C and at a stirring speed of 900 rpm. Platelets 
washed from PRP and resuspended as described above in buffer, pH 
7.4 (37”C), to a final concentration of 3-4 x lo* cell/ml. 0.5 ml of 
suspension was placed in an aggregometer cuvette, subsequently 
1 mM CaCl2 and 0.8 mg/ml fibrinogen (Serva) were added. 
In experiments with inhibitors, the cells were incubated, 5 min 
prior to ADP (10 FM final, Sigma) activation, with either correspon- 
dent inhibitor or vehicle (control). 
3. RESULTS AND DISCUSSION 
In our experiments, 1OyM ADP produced a rise in 
[CatfIr from the basal level of 120 + 10 nM to 700 t 
80 nM (n = 20). Fig.lA shows typical ADP-induced 
Ca2’ signals in cells suspended in control medium 
(curve 1) or in medium containing 20 FM NDGA. In 
the latter case, Ca2+ signal was almost completely 
abolished. The dose-response curve for the effect of 
NDGA on ADP-induced Ca2+ signals (fig. 1 B) gives an 
ICSO value of about 1 FM. A similar dose-response rela- 
tion was obtained in studying the effect of NDGA on 
platelet aggregation (f&.2). 
The I& vaiue proved to be close to those obtained 
for NDGA-induced LPG pathway inhibition on 
neurones and neutrophils [ 15,161. Another lipoox- 
ygenase inhibitor, compound BW-755C, also caused an 
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Fig. 1. (A) Effect of NDGA and indomethacin on ADP-induced Ca” 
signals in platelets. Representative fluorescent tracing from 3-8 
experiments are shown. ADP, lO/rM. (B) Dose-response dependence 
of NDGA inhibitory effect. 100% - [Ca*+]i increase in control 
sample. 
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Fig.2. (A) Effect of NDGA and indomethacin on ADP-induced 
platelet aggregation. Representative aggregation tracing from 3-5 
experiments are shown. ADP, IOpM. (B) Dose response dependence 
of NDGA inhibitory effect on platelet aggregation. 100% - 
aggregation amplitude in control sample. 
effective inhibition of platelet aggregation and Ca2+ 
signal (fig.3). 
In order to ascertain that the effects of NDGA and 
BW-755C described resulted from altered AA 
metabolism, we performed experiments with platelets 
treated with 4-bromophenylacyl bromide, the inhibitor 
of phospholipase A2 and C, which is known to prevent 
AA liberation from membrane phospholipids [ 11,13 J.
Fig.3 shows that addition of 20pM 4-bromophen- 
ylacyl bromide to a platelet suspension led to a highly 
significant inhibition of both Ca2+ signal and platelet 
aggregation. 
In contrast to the LPG and phospholipase inhibitors, 
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Fig.3. Effect of inhibitors of AA metabolism on ADP-induced Ca2’ 
signals (upper panel) and platelet aggregation (lower panel). All 
inhibitors were used at a concentration of 20pM. 100% - platelet 
response in control cells. 
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the inhibitor of cyclooxygenase, indomethacin 
(20 PM), caused only a very small decrease in Ca2+ 
signal (see fig.1) and a partial suppression of platelet 
aggregation, which at the same time became partially 
reversible (fig.2). The Ca’+-signal resistance in ADP- 
activated platelets to indomethacin has been reported 
earlier [7]. A small decrease in this signal shown in fig. 1 
may be attributed to side effects of indomethacin, since 
at a concentration higher than 5 PM it also affects the 
LPG [II]. 
These experiments uggest a crucial role for the LPG 
pathway in the generation of Ca2+ signals and aggrega- 
tion of human platelets for which there are two possible 
explanations. 
On the one hand, one or more LPG metabolites of 
AA could leave the stimulated cell, in which they are 
generated, and act as first messengers on the platelet 
membrane receptors, thus activating in some unknown 
fashion receptor-operated Ca2+ channels. This sugges- 
tion, however, is not supported by the following data. 
As mentioned above, 12-HETE, one of the principal 
LPG metabolites of AA in human platelets [l], exerts 
an inhibitory influence on platelet aggregation caused 
by AA, when applied externally [9]. However, the ef- 
fect of 12-HETE on ADP-induced platelet aggregation 
has not yet been studied. According to Westlund et al. 
[17] LPG metabolism of AA is not terminated by the 
generation of 1ZHETE and 12-HPETE in platelets, 
but leads to formation of a leukotriene-like substance 
and dihydroxyeicosanoid acids. Leukotrienes in other 
cell types (e.g. lymphocytes, neutrophils) are known to 
induce activation of Ca2+ influx in response to stimula- 
tion [ 181. Thus, it is reasonable to search for LPG 
metabolites of AA in platelets that could be involved in 
their autocoid activation. 
On the other hand, some of the LPG metabolites of 
AA may play a role as intracellular second messengers 
whose generation is a prerequisite for ADP-induced ac- 
tivation of Ca2+ channels. Here one could speculate 
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about a possible effect of this metabolite on G-proteins 
mediating the receptor Ca2+-channel coupling. 
Whatever the exact mechanism of LPG products in- 
volved in Ca2+-signal regulation, maybe their participa- 
tion is important for understanding the mechanism of 
platelet activation. 
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